Regulation of calcium metabolism in pseudohypoparathyroidism type 1b. From genotype to physiopathology  by Sobrinho, Luis G. et al.
OR
1
L
a
b
c
d
a
A
R
A
A
K
1
H
M
P
P
1
H
M
P
1Rev Port Endocrinol Diabetes Metab. 2014;9(1):2–6
Revista  Portuguesa
de  Endocrinologia,  Diabetes  e  Metabolismo
w ww.elsev ier .p t / rpedm
riginal  article
egulation  of  calcium  metabolism  in  pseudohypoparathyroidism  type
b.  From  genotype  to  physiopathology
uis  G.  Sobrinhoa,∗, Branca  M.  Cavacob,c, Hugo  G.  Ferreirad
Servic¸ o de Endocrinologia, Instituto Português de Oncologia de Francisco Gentil, Lisboa, Portugal
Unidade de Investigac¸ ão de Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Francisco Gentil, Lisboa, Portugal
Centro de Estudos de Doenc¸ as Crónicas (CEDOC), Faculdade de Ciências Médicas, Lisboa, Portugal
Rede de Química e Tecnologia (REQUIMTE), Departamento de Química, Universidade Nova de Lisboa, Caparica, Portugal
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 29 October 2013
ccepted 6 May  2014
vailable online 5 July 2014
eywords:
,25 dihydroxy vitamin D
ypocalcemia
athematical models
seudohypoparathyroidism
a  b  s  t  r  a  c  t
Objective:  Pseudohypoparathyroidism  type  1b  (PHP1b)  results  from  methylation  defects  in the maternal
GNAS  locus.  It is  implied  that  the  observed  hypocalcemia  results  from  impairment  of  renal  vitamin  D  1
hydroxylase.  This  study  was  undertaken  to clarify:  (1)  How  serum  concentrations  of calcium,  phosphate,
PTH and  1,25 dihydroxy  vitamin  D (1,25OH2D)  relate  to each  other in patients  with  PHP1b;  (2)  how  a
mathematical  model  of calcium  metabolism  could  reproduce  the  observed  ﬁndings.
Patients:  The  study  included  139  untreated  patients,  retrieved  from  the  literature,  with  simultaneous
measurements  of Ca,  P and  PTH  of whom  25  had  measurements  of 1,25OH2D.
Results:  Mean  values  and  standard  errors  of  the  mean  (SEM)  were:  PTH  = 43 pM  (3.66);  P =  2.16 mM
(0.056);  Ca  = 1.69  mM  (0.038);  1,25OH2D  = 84 pM (10.9).  Phosphate  correlated  negatively  with  calcium
(R  =  −0.590;  p  < 0.001)  and  with  age  (R  = −0.623;  p < 0.001).  No  other  correlations  were  observed.  The
mathematical  model  simulated  closely  the biochemical  pattern  of PHP1b  when  the  clearance  of  phos-
phate  was reduced  to 20%,  the  clearance  of  calcium  was  doubled  and  the response  of  1  hydroxylase  was
reduced  to 30%.
Conclusions:  (1)  In  PHP1b  the  concentrations  of  1,25OH2D  are  mostly  normal.  Therefore,  they  cannot
explain  the  observed  hypocalcemia;  (2)  hypocalcemia  can  only  be  explained  by  increased  fractional
excretion  of calcium  resulting  from  GNAS  haplo-insufﬁciency  at the  level  of the  distal  tubule;  (3)  the
use  of  mathematical  models  to simulate  complex  metabolic  systems  allows  the  extraction,  from  clinical
data,  of insights  onto  physiopathology  that  are  not  accessible  to  intuition  alone.
© 2013  Sociedade  Por-
tuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier  España,  S.L.  All rights  reserved.
Regulac¸ ão  do  metabolismo  do  cálcio  em  pseudohipoparatiroidismo  de  tipo  1b.
Do  genótipo  à  ﬁsiopatologia
alavras-chave:
,25 dihidroxi vitamina D
r  e  s  u  m  o
Objectivo:  O  pseudohipoparatiroidismo  tipo 1b  (PHP1b)  resulta  de  defeitos  de  metilac¸ ão  no  locus  materno
do  GNAS.  É  aceite  que  a hipocalcémia  que  se observa  nestes  casos  resulta  da consequente  inactivac¸ ão daipocalcemia
odelos matemáticos
seudohipoparatiroidismo
hidroxilase  1. Este  estudo  foi feito  para  caracterizar:  1) As  relac¸ ões  entre  as calcémias,  fosfatémias  e
concentrac¸ ões  de  PTH  e de  1,25  dihidroxi  vitamina  D (1,25OH2D)  nos  doentes  com  PHP1b;  2)  Se um
modelo  matemático  do  metabolismo  do cálcio  poderia  reproduzir  os  dados  observados.
Doentes: O estudo  incluiu  os casos  de 139  doentes  não  medicados,  extraidos  da  literatura,  e  que  tinham
medic¸ ões  simultâneas  de  Ca,  P  e  PTH.  Em  25  deles  tinham  também  sido  medidos  os valores  da  1,25OH2D.
Resultados:  Os  valores  médios  e o  erro-padrão  (SEM)  foram:  PTH  = 43  pM (3,66);  P =  2.16 mM  (0,056);
Ca  = 1.69  mM  (0,038);  1,25OH2D  = 84  pM  (10,9).  Os valores  da  fosfatémia  estavam  fortemente  correla-
cionados  com  os  da calcémia  (R  =  -0.590;  p <  0.001)  e com  a idade  age  (R = -0.623;  p <  0.001).  Não  se
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encontraram  outras  correlac¸ ões  signiﬁcativas.  O modelo  matemático  simulou  com  grande  aproximac¸ ão
o  padrão  hormonal  global  do  PHP  1b quando  a  depurac¸ ão de  fosfatos  foi  reduzida  para  20%,  a depurac¸ ão
de cálcio  foi  duplicada  e resposta  da 1  hidroxilase  foi  reduzida  a  30%.
Conclusões:  1) As concentrac¸ ões  de1,25OH2D  são  normais  na  maior  parte  dos  casos  de PHP1b.  Por  con-
sequência,  não  podem  explicar  a hipocalcémia;  2) A  hipocalcémia  só  pode  ser explicada  pelo  aumento
da excrec¸ ão fraccional  de  cálcio  resultante  da haplo-insuﬁciência  do GNAS  ao nível  do túbulo  distal;
3) O recurso  a modelos  matemáticos  que simulam  sistemas  metabólicos  complexos  permite  extrair,  a
partir  de  dados  da  rotina  clínica,  informac¸ ões  sobre  ﬁsiopatologia  que  não  são  acessíveis  ao  raciocínio
intuitivo.
© 2013  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Publicado  por  Elsevier
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Patients with pseudohypoparathyroidism type 1b (PHP1b)
resent resistance to parathyroid hormone (PTH) at the proximal
enal tubules. In this tissue, the G-protein alpha-subunit (Gs),
rom the PTH receptor-coupled G-protein, is not transcribed by
he paternal allele, being expressed mainly by the maternal allele,
ue to imprinting.1,2 Therefore, disruption of the GS encoding
ocus involving silencing of the maternal allele results in reduced
r absent GS activity. The consequent renal resistance to the
ctions of PTH is believed to increase the threshold for phosphate
xcretion and to reduce the synthesis of 1 hydroxylase. Hyper-
hosphatemia, hypocalcemia and high PTH levels are expected, and
bserved, consequences. Most encountered serum levels of 1,25
ihydroxyvitamin D (1,25OH2D) are within the normal range.
The present study was designed with two  purposes: (1) To
eﬁne the relationships between the serum concentrations of the
bserved variables (Ca, P, PTH and 1,25OH2D) in a population of
atients with PHP1b, extracted from the literature; (2) to ﬁnd out if
nd how feeding the primary abnormalities of PHP1b (resistance to
he effects of PTH on the threshold for phosphaturia and on the syn-
hesis of 1 hydroxylase) into a previously published mathematical
odel3,4 of calcium metabolism could reproduce the observed ﬁnd-
ngs on the patients.
aterials and methods
All articles selected in PubMed under the heading “pseudohy-
oparathyroidism” until August 2012 and their cross-references
ere screened for descriptions of actual cases of PHP1b. All cases
ith simultaneous, pretreatment, measurements of serum calcium,
hosphate and PTH were selected for the study.1,2,5–22 Two  addi-
ional cases without measurements of PTH but in which 1,25OH2D
ad been measured17 were included. Care was  taken to avoid
uplications of cases published on different occasions by the same
roups.
atients
A total of 139 cases were selected (80 females, 52 males, and 7
ith non-speciﬁed sex). Sixty-three of the cases were familial, 38
ere sporadic and this information was missing in 38. Twenty-ﬁve
f the patients also had measurements of 1,25OH2D. In 14 cases
TH had been measured by RIA directed at the amino terminal part
f the PTH molecule. In these cases the values were converted to
he equivalent values for the assays of “intact” PTH using a factor
 0.0165 – calculated from the reference ranges reported. Refer-
nce data for all the variables were checked for conformity with
23hose published by Kratz et al. for adults, generally accepted by
he medical community when local references are not available. As
xploratory analysis revealed that serum phosphate was correlated
ith age this variable was included in the correlation analysis.España,  S.L.  Todos  os  direitos  reservados.
For the correlations with 1,25OH2D only 23 patients were used,
because in 2 of them there was no information on PTH.
Statistics – The signiﬁcance of the differences between the aver-
ages of groups were calculated by the t-test. Two tailed Pearson’s
correlations between variables were calculated by bivariate analy-
sis and then by stepwise multiple regression analysis considering
each of the variables (except age) as a dependent variable. The
calculations were made using the software SPSS, version 19. Sig-
niﬁcance was deﬁned at the level of 5%.
Simulations
In order to compute the expected results of the pertinent vari-
ables (serum concentrations of calcium, phosphorus, PTH and
1,25OH2D) when the known defects observed in PHP1b were
considered, we  used an upgraded version3 of a mathematical
model of calcium metabolism published by our group.4 A source
code of the program can be obtained from h.g.ferreira3@gmail.com.
The parameters determining all the functions dependent on PTH
were relaxed so that: (1) The postulated abnormalities described
in PHP1b were included in the equations; (2) the outcoming values
for the pertinent variables at steady state would mimic  as much as
possible the average values from the observed series.
Results
Descriptive statistics of the variables
The serum levels of calcium, phosphorus and 1,25OH2D had a
Gaussian distribution. Age and the concentrations of PTH had a log
normal distribution. All variables had unimodal distributions.
The number of cases (n), mean, standard error of the mean (SEM)
and range of each of the variables is shown in Table 1.
When the patients were grouped by sex it was  found that
the mean age of the males was signiﬁcantly lower than that
of the females (13.3 vs. 21.5 years; p = 0.001) and the phosphate
levels were signiﬁcantly higher in males than in females (2.29 vs.
2.01 mM;  p = 0.007). No signiﬁcant differences were observed for
the other variables. When the patients were grouped as sporadic
(n = 38) vs. familial (n = 63) cases no differences were found in sex
(36/27 females in familial cases vs. 21/17 in sporadic cases), age
(16 vs. 19.5 years), calcium (1.61 vs. 1.75 mM), phosphate (2.08 vs.
2.07 mM)  or PTH (47.7 vs. 44.4 pM).
Correlations
Phosphate levels correlated negatively with calcium levels
(t = −7.668; p < 0.001) and with age (t = −7.253; p < 0.001) on
multiple regression analysis considering age, serum calcium con-
centrations and PTH as independent variables. No other signiﬁcant
correlations were observed. In patients aged 39 years or older
the concentrations of PTH were positively correlated with that of
4 L.G. Sobrinho et al. / Rev Port Endocrinol Diabetes Metab. 2014;9(1):2–6
Table  1
Number of patients with PHP-1b and mean, SEM and range of the variables.
Age (years) Ca (mM) P (mM)  PTH (pM) 1,25OH2D (pM)
n 123 137 137 137 25
Mean 18.7 1.69 2.16 43 84
SEM  1.21 0.038 0.056 3.66 10.9
Range 3–61 0.90–2.95 0.81–3.42 5.83–258 15–203
Reference rangea – 2.25–2.63 0.97–1.45b 1.1–6.6 63–113
a Reference ranges according to Kratz et al.23
b Reference for adults.
Table 2
Changes in the parameters introduced in the model so that the presumed con-
sequences of the genetic defects characteristic of PHP1b are included and the
outcomes, at steady state, mimic the empirical results observed in the present series.
Parameter Change introduced in the model
Clearance of phosphate by the
kidney
Reduced to 20% of the reference
value
Clearance of calcium by the kidney Increased by 100% of the reference
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tvalue
Responsiveness of 1 hydroxylase
to PTH
Reduced to 30% of the reference
value
alcium (t = 2.501; p = 0.041). This subgroup was selected because
9 years was the age of the youngest patient with PHP and docu-
ented tertiary hyperparathyroidism.20 The correlations between
he serum concentrations of PTH and those of calcium and phos-
hate remained not signiﬁcant even after this subgroup of patients
ere removed.
imulations
The model could simulate the observed hypocalcemia only
n the condition that the clearance of calcium was increased above
he reference value. The best simulation of all the observed vari-
bles was obtained introducing in the model the adjustments in
he parameters shown in Table 2.
The magnitude of the reduction in the responsiveness of 1
ydroxylase to PTH is difﬁcult to anticipate considering that this
nzyme is also expressed at the level of the distal tubule.24 It
eemed, therefore reasonable to consider that this defect was less
ntense than that on the clearance of phosphate.
Modiﬁcations on the parameters describing the effect of PTH on
he production of ﬁbroblast growth factor 23 (FGF 23) and on the
uxes of calcium to and from the bone were also relaxed but
he effects on the pertinent variables were small. The predicted val-
es of the variables at steady state and the average of the actually
bserved values in the patients are shown in Table 3.
iscussion
Hypoparathyroidism type 1b is an interesting model to study
he translation of well deﬁned abnormalities at the genetic/cellular
evel into their systemic repercussions. An epigenetic abnormal-
ty consisting of methylation defects at the maternally derived
NAS locus, paternally imprinted at the proximal renal tubule1,2,25
s present in these patients. It has been generally accepted that
able 3
alues of the variables calculated by the model compared to the values observed in
he  present series.
Variable Simulated Observed
Phosphoremia (mM)  2.10 2.16
Calcemia (mM)  1.75 1.69
PTH  (pM) 44 43
1,25OH2D (pM) 77 81this abnormality is responsible for the observed resistance to the
actions of PTH resulting in hyperphosphatemia and hypocalcemia
due to increased threshold for phosphate excretion and reduced
synthesis of 1 hydroxylase. Yet, no quantitative studies on the
excretion of phosphate or on the activity of 1 hydroxylase have
been reported in these patients or even in animal models.
An increase in the threshold for phosphate can explain the
observed hyperphosphoremia, leading to increased PTH, while the
impaired synthesis of 1 hydroxylase should result in reduced lev-
els of 1,25OH2D, a lowering of serum calcium concentration and
a further increase in the concentrations of PTH. The ﬁnding of a
normal concentration of 1,25OH2D in one of our patients16 raised
doubts about the validity of this explanation and prompted us to
perform a meta-analysis of the available literature on this matter
considering that PHP1b is a rare condition.
In a series of 7 untreated patients with pseudohypoparathy-
roidism type 1, subtype not speciﬁed (PHP1?), the authors reported
average 1,25OH2D levels below normal (37 pM/l vs. 100 in
controls).26 This series was not included in our analysis since the
authors provided only average values for 1,25OH2D. However,
in the 27 patients collected for the present study it was found that
the scatter of values of 1,25OH2D contained the normal range. This
might be explained by the high values of PTH, but cannot explain
the observed hypocalcemia. Hypocalcemia could be due to some
degree of resistance to parathyroid hormone at the level of the
distal renal tubule and consequent increase in the calcium excre-
tion when normalized for the corresponding glomerular load. The
responsiveness to PTH at this level is believed to be preserved,
since an infusion of PTH in patients with PHP1? reduces the uri-
nary excretion of calcium24,27 and, for similar levels of calcium,
patients with PHP1? excrete less calcium than patients with idio-
pathic hypoparathyroidism, both groups being under treatment
with 1 hydroxyl vitamin D.24,28
While reduction in the excretion of calcium after an infusion of
PTH indicates that the distal nephron responds to PTH it does not
establish that the response is quantitatively normal. Evidence that
the distal nephron is affected in patients with PHP1? is provided
by the ﬁnding that the urinary excretion of cathepsin D (a marker of
distal tubular function) following an infusion of PTH is signiﬁcantly
reduced in patients with PHP1? as compared to normal controls
or to patients with idiopathic hypoparathyroidism.26 This observa-
tion probably reﬂects haplo-insufﬁciency of GNAS in non imprinted
tissues of patients with PHP1?, a ﬁnding described in mice knocked-
out for the gene GNAS.25 The only way to quantitatively assess the
re-absorption of calcium by the distal nephron is by calculating
the fractional excretion of calcium. To the extent of our knowledge
only one report in the literature contains data in untreated patients
with PHP1?24 that allow such calculation. In the ﬁve patients with
PHP1? in which this ratio could be computed it was 0.0195 ± 0.0046
while in 10 patients with idiopathic hypoparathyroidism reported
in the same publication it was 0.0316 ± 0.0059. This was  com-
pared with 0.0109 ± 0.0009 in our own  series of 41 normal controls.
Although only the difference between controls and hypoparathy-
roid patients reached a level of statistical signiﬁcance (p < 0.001),
most likely due to the small sample size of patients with PHP1?,
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hese observations suggest that patients with PHP1? live in a steady
tate such that the fractional excretion of calcium by the kidney
s higher than normal but lower than that observed in idiopathic
ypoparathyroidism. This is what could be expected considering
he GNAS haplo-insufﬁciency at the level of the distal nephron.25,26
he possibility that, as a result of a positive balance of phosphate,
 direct physical effect of the hyperphosphatemia could contribute
o the observed hypocalcemia is suggested by the observation that
hen increased quantities of phosphate are added to aliquots of the
ame blood sample a perfect negative correlation between concen-
rations of ionized calcium and phosphorus is observed.29 However,
iving organisms exist in a steady state of ﬂuxes, not in equilibrium,
s in a ﬂask. For the product of solubility to be a determinant factor
f hypocalcemia one would expect continuous accretion of calcium
n the bone or somewhere else as occurs in familial tumoral calci-
osis a condition wherein, despite the extensive calcinosis, serum
alcium concentrations are usually kept within normal limits. Cases
f osteosclerosis30 or of extensive soft tissue calciﬁcation31 in
HP1b have been reported but are exceptional and most patients
ith PHP1b present lower bone mass density than normal controls
r patients with hypoparathyroidism.32,33
The simulations performed with the mathematical model of
alcium metabolism provided support to the formulation that
aplo-insufﬁciency of the GS encoding locus at the level of the dis-
al tubule results in a reduction of its responsiveness to the calcium
paring function of PTH.
When the fractional excretion of calcium by the kidney was
ncreased to twice as much its reference value (a factor calcu-
ated from the reported cases by Yamamoto,24 and reasonable to
xpect given the haplo-insufﬁciency) the model closely reproduced
he empirical observations extracted from the reported literature,
ncluding the somewhat bizarre ﬁndings of hypocalcemia in the
resence of high values of PTH and normal serum concentrations
f 1,25OH2D.
No differences in the metabolic phenotype were found between
poradic and familial cases. The genetic basis of the familial forms
s rather homogeneous, in most cases consisting of a deletion of
bout 3 kb in the STX16 gene. Unidentiﬁed genetic causes account
or most sporadic forms although, along with familial forms, the
bnormalities converge to the same ﬁnal defect – loss of the mater-
al epigenotype within the exon 1A DMR. Considering the small
ample size and the different methods used by different authors at
ifferent times no attempts were made to further sub divide the
opulation according to the genetic abnormalities.
Phosphate levels were negatively associated with age, a ﬁnd-
ng already described in healthy people.34 This association may  be
esponsible for the signiﬁcantly higher phosphate levels observed
n males (2.29 vs. 2.00 mM)  as the average age of the males in the
ample was signiﬁcantly lower than that of the females (13.3 vs.
1.5 years).
It is interesting that the serum concentrations of PTH, although
onsistently high did not correlate with calcium, phosphorus or
,25OH2D except in older patients in whom documented20
r presumed tertiary hyperparathyroidism may  occur. Factors
esponsible for the elevation of PTH are hypocalcemia, hyperphos-
hatemia and, when present, low concentrations of 1,25OH2D. The
bsence of correlations between these variables is certainly due
o the complexity of the non-linear multi-loop system regulating
alcium metabolism.
Conclusions: (1) In PHP1b the concentrations of 1,25OH2D are
nappropriately normal, scattered over an interval that contains
he normal range. Therefore, reduced activity of 1 hydrox-
lase cannot explain the consistently observed hypocalcemia;
2) hypocalcemia is most likely due to an increased fractional
xcretion of calcium resulting from GNAS haplo-insufﬁciency at
he level of the distal tubule; (3) although the genetic defects in
1l Diabetes Metab. 2014;9(1):2–6 5
PHP1b affect predominantly the excretion of phosphate and the
activity of 1 hydroxylase, the physiopathology of the condition is
ultimately determined by the altered fractional excretion rate of
calcium, besides that of phosphate. The reduced responsiveness of
1 hydroxylase to PTH is offset by the high levels of PTH; (4) the use
of mathematical models to simulate complex metabolic systems
allows to extract, from clinical data, information on physiopathol-
ogy that is not accessible to intuition alone.
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